Parathyroid Scintigraphy

Parathyroid Scintigraphy

Hyperparathyroidism

Objectives
  • Anatomy and Physiology
  • Pathophysiology
  • Protocol
    • Radiopharmaceutical, dose
    • Imaging parameters/acquisition
  • Indications
  • Contraindications
  • Precautions
  • Review of images
Anatomy
  • Location:
    • Situated on the posterolateral surface of the upper and lower thyroid lobes.
  • Glands:
    • Typically four parathyroid glands.
    • Normal size resembles that of rice but can be as large as a pea.
    • Characteristic mustard yellow color.
Ectopic Sites
  • Ectopic parathyroid glands can be found in:
    • Thymus
    • Neck
    • Chest
    • Embedded within the thyroid gland.
    • Surrounded by a sheath related to the carotid artery and jugular vein.

Parathyroid Hormone (PTH) Function

  • Calcium Regulation:
    • Plays a vital role in maintaining calcium homeostasis, specifically in the range of 8-10 mg/dL.
  • Vitamin D Metabolism:
  • Negative Feedback Loop:
    • When blood calcium levels decrease, PTH is released.
    • PTH acts on:
    • Kidneys: Retains calcium and activates Vitamin D.
    • Intestines: Increases absorption of calcium.
    • Skeletal System: Stimulates osteoclasts that resorb bone tissue.

Symptoms and Effects of Hyperparathyroidism

  • Digestive System:
    • Loss of appetite
    • Nausea and vomiting
    • Constipation
  • Nervous System:
    • Fatigue
    • Depression
    • Confusion
  • Musculoskeletal System:
    • Muscle weakness
    • Aches and pains in bones and joints
  • Urinary System:
    • Kidney stones
    • Increased thirst
    • Increased urination

Types of Hyperparathyroidism

  • Primary Hyperparathyroidism:
    • Caused by parathyroid gland pathology.
    • Characterized by elevated PTH (normal range: 10-65 pg/mL) and normal or elevated calcium levels.
    • Causes may include solitary or multiple adenomas or hyperplasia.
  • Secondary Hyperparathyroidism:
    • Occurs due to conditions causing hypocalcemia.
    • Elevated PTH with normal or low serum calcium.
    • Often related to chronic renal disease, known as renal hyperparathyroidism (HPT).
  • Tertiary Hyperparathyroidism:
    • Develops during the course of secondary hyperparathyroidism.
    • Characterized by elevated calcium and PTH due to untreated secondary hyperparathyroidism and autonomous PTH adenoma.

Clinical Presentation of Primary Hyperparathyroidism (PHPT)

  • Most common presentation is asymptomatic hypercalcemia.
  • Other observations include:
    • Elevated or high-normal intact PTH concentration.
    • Elevated or normal serum calcium levels.
    • Potentially leading to bone pain, muscle weakness, osteoporosis, or fractures.
  • Treatment: Surgical resection.

Secondary Hyperparathyroidism

  • Causes include:
    • Renal insufficiency
    • Vitamin D deficiency
    • Malabsorption
    • Osteomalacia and rickets.
  • Associated symptoms:
    • Bone pain
    • Muscular weakness
    • Osteoporosis/osteopenia
    • Risk of fractures.
  • Treatment: Reducing phosphate uptake, calcium-containing preparations that bind phosphates, and Calcitriol supplementation. Surgery may also be an option.

Tertiary Hyperparathyroidism

  • Characterized by:
    • Hypercalcemia arising during secondary hyperparathyroidism.
    • Autonomous PTH adenoma leading to continual PTH secretion from hyperplastic glands.
  • Accompanied by elevated PTH and calcium levels.

Comparative Overview of Hyperparathyroidism Types

TypePathologySerum PTH LevelSerum Calcium LevelManagement
PrimaryHyperfunctioning due to adenoma, hyperplasia, or carcinomaHighHigh/NormalSurgery; Cinacalcet if surgery is not feasible
SecondaryPhysiological stimulation due to hypocalcemiaHighLow/NormalTreatment of underlying cause; Cinacalcet
TertiaryFollowing long-term stimulation leading to hyperplasiaVery HighHigh/NormalCinacalcet; Surgery if unresponsive

Quiz Questions

  • Question 1: When blood calcium levels are low, PTH stimulates:
    • A. Urinary excretion of calcium by the kidneys.
    • B. A reduction in calcium absorption from the intestines.
    • C. The activity of osteoblasts.
    • D. The activity of osteoclasts.
  • Question 2: Which of the following can result from hyperparathyroidism?
    • A. Increased bone deposition.
    • B. Fractures.
    • C. Convulsions.
    • D. All of the above.
Clinical Refreshers
Parathyroid Scintigraphy
  • Focus on the most commonly performed clinical practices.
Indications for Parathyroid Scintigraphy
  • Detection and localization of:
    • Primary and secondary hyperparathyroidism.
    • Identification of single or multiple adenomas or glandular hyperplasia in patients.
  • Localization for surgical intervention.
  • Identifying parathyroid tissue post-surgery for persistent or recurrent hyperparathyroidism (elevated PTH and calcium levels).
Contraindications
  • Patients unable to remain still (e.g., agitated, claustrophobic).
  • Pregnancy or lactation.
Patient History Questions
  • Previous lab results for calcium (Ca2+) and PTH levels.
  • Possible Vitamin D levels.
  • Results of DMI test.
  • History of thyroid disease, especially nodular thyroid disease.
  • Recent iodine-containing contrast or thyroid hormone treatments.
  • If thyroid imaging and subtraction studies are involved.
  • Previous thyroid surgeries or treatments (e.g., Thyroidectomy or RAI therapy).
  • Symptoms such as muscle fatigue, osteoporosis, kidney stones, and neck tenderness/swellings.
Dual Phase Method
  • Overview: Evaluates the distribution of the radiopharmaceutical over several hours, divided into two phases:
    • Thyroid phase: Initial uptake observed in thyroid and surrounding tissues including salivary glands, heart, gallbladder, and gut, but with possible indistinctiveness in parathyroid.
    • Delayed phase: Focused imaging to observe specific parathyroid uptake.
Radiopharmaceuticals Used
  • Commonly used agents:
    • Tc99m sestamibi or Tc99m tetrofosmin:
    • Standard dose: 740 MBq (20 mCi) IV.
    • Range: 740–1110 MBq (20–30 mCi).
    • Mechanism of Action: Passive transport correlating with blood flow to thyroid and parathyroid tissue, remaining longer in adenomatous and hyperplastic tissue.
Single Isotope Imaging Protocol (Tc99m sestamibi)
  • Early Phase (Thyroid Phase):
    • Inject Tc99m sestamibi and wait 10-30 min.
    • Patient in waters position.
    • Scanning neck and chest through SPECT or SPECT/CT imaging.
Imaging Parameters for SPECT
  • Imaging duration: approximately 25 minutes.
  • Configuration: circular or non-circular, with 360° rotation.
  • Matrix dimensions: 128 x 128, with 120 projections, and stop duration of 15-25 sec per capture.
Delayed Phase Imaging
  • At 1.5-2.5 hours post-injection: perform repeat imaging of the neck and chest, using planar, SPECT, or SPECT/CT as required.
Other Radiopharmaceuticals for Dual Isotope Imaging
  • Tc99m pertechnetate: used with a dosage of 74 MBq (2 mCi) IV, with a range of 74–370 MBq (2–10 mCi).
  • I123 NaI: administered orally at 7.5 MBq (200 µCi), with a range from 7.5–22 MBq (200–600 µCi).
Dual-isotope Protocol Options
  • First Option:

    • Administer Tc99m pertechnetate, wait 30 minutes, and capture anterior images.
    • Inject Tc99m sestamibi, wait 10 minutes, repeat imaging.
  • Second Option:

    • Administer Tc99m sestamibi first, wait 10 minutes, then inject Tc99m pertechnetate, waiting 30 minutes before imaging.
Dual-Isotope Protocol (123I/99mTc-sestamibi)
  • First, administer 123I, wait 4 hours, then capture anterior neck and chest images.
  • Administer Tc99m sestamibi, wait 10 minutes, and repeat imaging.
Image Processing
  • Scale planar images to accurately visualize areas of normal anatomy.
  • Label images with projection information and any dose or technologist identification.
  • Process SPECT or SPECT/CT images according to manufacturer recommendations.
  • Normalization and Subtraction:
    • For dual-isotope protocols, normalize images to total thyroid counts and then apply computer subtraction method to obtain clearer images.
Summary
  • Various imaging techniques are brought together for parathyroid scintigraphy, focusing on the detection and management of hyperparathyroidism issues through a detailed, phased approach using specific radiopharmaceuticals and imaging protocols.